Highest-materiality recent filing
Immunocore shareholders approve all 10 resolutions at 2026 AGM
Reappointment of directors Siddharth Kaul, William Pao, Kristine Peterson passed; Peterson had 8.7M against (22.5%).
Immunocore Q1 KIMMTRAK net sales $106.7M (+14% YoY); net income $13M vs $5M
KIMMTRAK net sales $106.7M, up 14% YoY; US sales $67.4M (+19.1% YoY), Europe $34.4M.
Immunocore reports Q4 2025 KIMMTRAK sales of $104.5M, FY $400M; TEBE-AM data 2H 2026
Q4 2025 KIMMTRAK net sales $104.5M (+24% YoY); FY2025 $400.0M (+29% YoY).
Immunocore R&D Head David Berman resigns effective Feb 27; no replacement planned
David Berman notified resignation as Head of R&D on Jan 27, 2026, effective Feb 27, 2026.
Preliminary unaudited cash, cash equivalents and marketable securities ~$864M as of Dec 31, 2025.
Immunocore board member Krishana resigns; CHRO St. Leger to depart in May 2026
Ranjeev Krishana resigned from Board and Remuneration Committee effective Nov 26, 2025; no disagreement with company.
Immunocore Q3 2025 KIMMTRAK sales $103.7M, up 29% YoY; net loss $0.2M vs profit $8.7M
KIMMTRAK net revenue $103.7M (Q3); $295.5M YTD, up 31% YoY; US sales $67.3M, Europe $33.5M.
Immunocore Q2 2025: KIMMTRAK revenue $98M (+30% YoY); net loss $10.3M
Q2 2025 net product sales of $98.0M, up 30% vs. $75.3M in Q2 2024; US sales $64.1M, Europe $33.0M.
Immunocore 2025 AGM: all 13 resolutions passed, director Herbst re-elected with narrow margin
Re-appointment of director Roy S. Herbst: 17.3M for, 15.5M against (47% oppose).
Immunocore Q1: KIMMTRAK revenue $93.9M (+33% YoY); net income $5M vs loss year ago
KIMMTRAK net sales $93.9M, up 33% YoY; US $56.6M, Europe $32.8M (incl $6M favorable adjustments), intl $4.5M.
Immunocore registers up to $150M of 2.50% convertible notes for resale by selling holders
Filed prospectus supplement on March 17, 2025 covering resale of up to $150M aggregate principal of 2.50% Convertible Senior Notes due 2030.
Well tolerated across 60-300 mcg doses; no dose-limiting toxicities or serious AEs; mild CRS in 5 of 6 at 300 mcg.
Immunocore reports 2024 KIMMTRAK net sales of $310M; appoints William Pao to board
KIMMTRAK Q4 net sales $84.1M; full year $310.0M (+30% YoY); net loss $51.1M ($1.02 EPS) vs $55.3M in 2023.
Immunocore reports ~$820M cash; three Phase 3 melanoma trials; new autoimmune candidate
Preliminary cash ~$820M as of Dec 31, 2024; Pharmakon loan prepaid in full.
Immunocore appoints Travis Coy as EVP, CFO, Head of Corporate Development effective Jan 1, 2025
Annual base salary $500,000; target cash bonus 40% of salary; sign-on bonus $200,000 in three installments.
Immunocore prepays $52M Pharmakon loan, terminating agreement 4 years early
Immunocore prepaid $52M ($50M principal, $0.5M interest, $1.5M prepayment premium) on Nov 8, 2024.
Immunocore Q3 2024: KIMMTRAK revenue $80.2M (+28% YoY); EPS $0.17; CFO to depart
KIMMTRAK net revenue $80.2M in Q3 2024, up 28% vs $62.6M in Q3 2023; US $57.3M, Europe $21.0M.
Immunocore reports positive Phase 1 data for brenetafusp in ovarian cancer at ESMO 2024
Phase 1 monotherapy: 58% disease control, 6.5% RECIST response rate, median PFS 3.3 months in heavily pre-treated platinum-resistant ovarian cancer.
Immunocore CFO Brian Di Donato resigns, effective Dec 31, 2024, to become CEO at private biotech
CFO and Head of Strategy Brian Di Donato resigns effective Dec 31, 2024, to become CEO at a private early-stage biotech in San Diego.
Immunocore reports Q2 2024 revenue growth of 32% driven by KIMMTRAK sales of $75.3 million
KIMMTRAK net revenues were $75.3 million in Q2 2024, up 32% year-over-year, driven by US growth and global expansion.
Immunocore reports Phase 1 brenetafusp data: 56% disease control in checkpoint pre-treated melanoma
Brenetafusp monotherapy in 47 late-line cutaneous melanoma patients showed 56% DCR (4 PR, 16 SD) and 4.2 months median PFS in PRAME+ patients.
Immunocore converts TEBE-AM to registrational Phase 3 evaluating KIMMTRAK for cutaneous melanoma
Trial converted to Phase 3 registrational after FDA consultation; three arms: KIMMTRAK monotherapy, KIMMTRAK+pembrolizumab, control.
Immunocore appoints Baker Bros partner Krishana to board; grants registration rights to BBA funds
Appointed Ranjeev Krishana (Baker Bros partner) as Class I director, effective May 28, 2024.
Bahija Jallal re-elected with 34.24M for (99.96%); Sir John Bell re-elected with 30.13M for (87.95%).
Immunocore Q1 KIMMTRAK sales $70.3M (+36% YoY); brenetafusp ASCO data; cash $832.8M
KIMMTRAK net sales $70.3M, up 36% YoY; US $50.0M, Europe $19.0M, international $1.4M.
Immunocore files prospectus supplement for resale of 1,220,063 ADSs by selling shareholder
Prospectus supplement filed on April 5, 2024, covering up to 1,220,063 ADSs for resale by a selling shareholder.
Immunocore FY2023 KIMMTRAK sales $238.7M; launches PRAME Phase 3 with BMS
Q4 2023 KIMMTRAK net sales $67.6M; full year $238.7M (+12% YoY). US $169.8M, Europe $67.6M.
the Board appointed William Pao, M.D., Ph.D. to serve as a Class II director of the Company, effective February 25, 2025.
In connection with his entry into the Employment Agreement, Mr. Coy resigned from the Company’s board of directors (the “Board”), effective as of the Effective Date.
On December 31, 2024, Immunocore LLC, an indirect, wholly owned subsidiary of Immunocore Holdings plc (“Parent” and, together with Immunocore LLC, the “Company”), entered into an employment agreement (the “Employment Agreement”) with Travis Coy, pursuant to which Mr. Coy will serve as the Company’s Executive Vice President, Chief Financial Officer and Head of Corporate Development as well as the Company’s principal financial officer, effective as of January 1, 2025 (the “Effective Date”).
Mr. Brian Di Donato notified Immunocore Holdings plc (the “Company”) of his decision to resign as Executive Vice President, Chief Financial Officer and Head of Strategy and principal financial officer of the Company, effective December 31, 2024, to pursue another opportunity.
the Board appointed Mr. Ranjeev Krishana to serve as a Class I director of the Company, effective May 28, 2024.
Max materiality 0.80 · Median 0.65 · Most common event earnings